Some clinicians also indicate that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can delay NAFLD progression (Toblli et al., 2008). This evidence concerns the gene ACE and metabolic dysfunction-associated steatotic liver disease.